with hypoglycaemic properties has been extracted from a wide variety of plant tissues ranging from cabbage and celery to yeastsl0. Little, Levine and B e d l found an insulin-like substance in the disintegration products of killed bacteria, while Collip12 extracted from clams (and also many plant sources) a substance, glucokinin, which produced marked hypoglycaemia when injected subcutaneously into rabbits. These preparations were usually toxic to the liver and this action is probably the basis of the hypoglycaemic effect.
Recently, two polypeptides, hypoglycin A and B, have been isolated from the unripe 'ackee', the fruit of a plant, Blighia sapida which probably produces the vomiting-sickness sometimes seen among the poorer classes in Jamaica13. Both produce a marked hypoglycaemic action when given orally and although they are hepatotoxic, they are of considerable interest as insulin is a polypeptide which is not effective by mouth. The chemical structure of hypoglycin A has recently1* been confirmed as the following: For example, oestradiol benzoate in large doses may reduce the hyperglycaemia of post-menopausal women suffering from diabetes15. Injections of dimercaprol sometimes produce a fall of blood-sugar concentration in diabetic patients who are receiving large doses of insulinls. Recently there has been renewed interest in the hypoglycaemic action of salicylates. Since the end of the last century, salicylates have been known to reduce the blood and urine sugar concentrations in diabetic patients1' but adequate doses of acetylsalicylic acid produce troublesome side-effects and this limits their clinical usefulness for the treatment of diabeteP. They probably act by enhancing the peripheral utilization of glucose. A fall of blood-sugar concentration associated with depletion of liver glycogen may be produced by salicylates in alloxan-diabetic rats and in animals made hyperglycaemic with cortisone19. Further, they stimulate glucose uptake by the isolated rat diaphragmz0, probably by uncoupling oxidative phosphorylation.
The present era of renewed interest in oral hypoglycaemic agents began in 1942 when Janbon, Chaptal, Vedel and Schaap21, while assessing the antibacterial properties of 5-isopropyl-2-sulphanilamido-1,3,4-thiadiazole (IPTD, R P 2254, I) in typhoid fever, discovered the dramatic hypoglycaemic action of the sulphonamide. A few of the patients died from hypoglycaemia. Between 1942 and 1946 , studies on the mode of action of IPTD and other thiadiazoles in dogs and rabbits were made by Loubati&res22 at Montpellier. He showed that IPTD (u) does not produce hypoglycaemia if the whole pancreas is removed but may do so if as little as one-sixth of the gland remains, ( b ) is most effective when injected directly into the pancreatic artery or through S-C.CHMe, ~s O z . N H . c~ 1 1
N-N NH2
( I ) the duct of Wirsung under pressure, (c) acts independently of the nervous system, (d) lowers the blood-sugar in inverse proportion to the bloodsulphonamide level, and ( e ) raises the respiratory quotient after glucose administration. He postulated a pancreaticotropic mechanism to explain these actions of IPTD.
In 1946 Chen, Anderson and Maze23 reported on the hypoglycaemic effect in intact rabbits of another thiadiazole, 5-cyclopropyl-2-sulphanilamido-l,3,4-thiadiazole. They showed that the compound was inactive or sometimes hyperglycaemic in animals with severe alloxan diabetes.
More recently the hypoglycaemic properties of many other sulphonamide derivatives have been discovered. This account is concerned chiefly with the new arylsulphonylurea compounds and the guanidine derivatives.
ARYLSULPHONYLUREA COMPOUNDS
Since 1955, when a group of German w0rkers~*-~6 published clinical observations on the potent hypoglycaemic action of a sulphanilamide derivative, N-butyl-N'-sulphanilylurea (carbutamide, 11) many hundreds of chemically related compounds have been studied for their hypoglycaemic activity.2ea N H , --( -Jso,. NH, co . NHBu 
(II) Carbutamide
The synthesis of arylsulphonamides, N-arylsulphonylcarbamates, N-aryl-N'-alkylureas and of alkyl and other substituted sulphonylureas has been d e~c r i b e d~' -~~. The majority of these compounds are too toxic for human use but two analogues of carbutamide, namely tolbutamide, (111) and chlorpropamide ( I V ) have been subjected to extensive clinical and pharmacological studies in the past few years. After large-scale laboratory investigation and clinical trial in the United States of America, Canada and the United Kingdom, carbutamide was withdrawn from clinical use owing to the high incidence of serious toxic side-effects. About 5 per cent of 7,193 patients developed skin rashes, gastro-intestinal disorders, severe leucopenia, liver damage and generalized sulphonamide sensitivity reactions; eight patients died 10-30 days after commencing treatment30. However, tolbutamide (introduced in 1956) and more recently chlorpropamide, have been widely used without serious ill effects in the treatment of mild diabetes mellitus of the adult type. Doubtless other similar compounds will become available for clinical trial in the future, but their advantages and disadvantages may always have to be measured against the extensive data collected about tolbutamide and chlorpropamide. Already N-cyclohexyl-N'-(3-amino-4-toluenesulph0nyl)-urea (metahexamide, Euglycin, V ) , N-(3-aminobenzenesulphonyl) -N'-nbutylurea (Sucrida Berna, SB 1, V I ) and N-2-furfuryl-N'-p-toluenesulphonylurea, (furfuralurea, VII) have been used clinically although none of them offer any important new beneficial features.
(VfZ) Furfuralurea
This account will therefore be chiefly concerned with the chemistry, metabolic features, mode of action and clinical applications of tolbutamide and chlorpropamide. Although carbutamide is not now used clinically, the data obtained from its use will be reviewed, as this compound was the first hypoglycaemic arylsulphonylurea to be discovered and many of the original investigations were carried out with it.
Chemistry and Metabolic Features Carbutamide
Carbutamide (N-butyl-N'-sulphanilylurea, BZ55, U6987, Invenol or Nadisan, 11) has physical properties similar to other N-monosu bstituted sulphonamide derivatives, being a white crystalline substance which has weak acidic properties associated with the sulphamoyl group. It forms salts with alkalis and the sodium salts are easily soluble in water. Estimation of the free compound may be carried out in blood and urine by diazotization and coupling reactions3I.
In 1956, Ridolfo and kirtle^^^ showed that, as with the earlier sulphonamides, intestinal absorption of carbutamide after oral administration is rapid; the compound may be detected in the blood within 30 minutes after taking 2.5 g by mouth. The peak blood-level (10-15 mg/100 ml. whole blood) is reached in 3-4 hours (at which time only 3-4 mg/l00 ml. is acetylated) and after 6-7 hours the level begins to fall slowly. The decline of sulphonamide concentration in the blood behaves as a first-order exponential function, which gives a biological half-life of 30-60 hours33. Within 2-3 hours there is a definite lowering of blood-sugar concentration, the effective blood-level of carbutamide being 6-8 mg/l00 ml. 34 . The liver partially detoxifies carbutamide by acetylation and then the drug is slowly eliminated via the kidneys. The urine contains about 66 per cent of the free sulphonamide and 33 per cent of the acetylated derivative.
As with other sulphonamides containing a p-amino group, carbutamide has some antibacterial action, and thyroid function is temporarily impaired. MacKensie and M a~K e n s i e~~, for example, showed that various sulphanilamide derivatives may produce goitre in small experimental animals, and Anderson, Worth and Harris36 reported that this is also true of carbutamide. I n human beings with mild diabetes mellitus, large doses of carbutamide (4 g daily) considerably depress thyroid 1311 uptake3'. Longer term studies in 39 patients using therapeutic doses (2 g daily) .for 47 weeks showed that the thyroid 1311 uptake is depressed to about 20 per cent of the pretreatment value by the end of the third week of therapy, and remains below normal for about 9 weeks. According to Brown and Solomon38, the mechanism of the antithyroid effects of carbutamide in rats is inhibition of the organic binding of thyroidal iodide-an effect similar to that of propylthiouracil but only about 1/200th as strong.
Tolbutamide
In tolbutamide (N-butyl-N'-p-toluenesulphonylurea, Rastinon, Orinase, D.860, U.2043, IZI) thep-amino group of carbutamide has been replaced by a methyl group and this change of chemical structure is responsible for many important biological differences. I t is a white crystalline solid with a melting point of 128*5-129*5°C. I t is practically insoluble in water although it forms soluble salts with alkalis. It dissolves readily in acetone, chloroform and alcohol.
Since tolbutamide lacks a p-amino group it cannot be estimated by the Bratton and Marshall procedure, but spectrophotometric methods have been d e v e l~p e d~~~~~ for the determination of total tolbutamide in blood and urine, based on its intense ultra-violet absorption at 228 mp. After acidification with ~/15phosphoric acid, the serum is extracted with chloroform (which must be completely removed subsequently as chloroform also absorbs strongly at 228 mp). The solvent-free extract is then taken up in 95 per cent ethanol and shaken with charcoal before being estimated spectrophotometrically. This forms a useful and sensitive method for the range 1-25 mg/100 ml. but it lacks specificity; recoveries are good (85-90 per cent). Difficulties may be encountered with variations in the plasma blank33 and even slight degrees of haemolysis lead to spuriously high readings. The method developed by Toolan and Wagner41 for chlorpropamide (see below) has recently been found to be suitable for t o l b~t a m i d e~~ and is unaffected by haemolysis. McDonald and S a~i n s k i~~ and S~i n g l e r~~ have developed colorimetric procedures which are probably less satisfactory.
As with carbutamide, absorption of tolbutamide from the intestine is rapid and maximal blood levels are reached in 3-4 hoursB. Based on the blood levels (extrapolated to zero time) after a given oral dose, the volume of distribution of tolbutamide is found to approximate to that of the extracellular fluid space in man45 and in nephrectomized, eviserated rabbits46. I n contrast to carbutamide, the tolbutamide concentration begins to fall according to a first-order exponential curve as soon as the maximal blood level is reached, giving a biological half-life of about 4 hours, both in normal and diabetic s~b j e c t s~~~~~. There is considerable individual variation in the blood levels attained, but after 8-10 hours the concentration in most subjects has fallen below the minimum effective range of 6-10 mg/lOO ml. after optimal therapeutic doses by mouthB. Increasing the dose does not increase the blood level comparably and even with doses of 6 g the blood level 24 hours later is still below the minimum required. Some serum protein-binding probably occurs as tolbutamide does not penetrate into the c e r e b r~s p i n a l~~ or oedema fluid48. In man, tolbutamide is converted into a freely soluble, non-toxic, carboxylic acid ( N-butyl-N'-p-carboxyphenylsulphonylurea, VIII) by oxidation of the p-methyl This acid has no hypoglycaemic action but is responsible for a variable proportion (10-28 per cent in 24 hours after a single oral dose) of the total blood tolbutamide A small amount of N-butyl-N'-p-hydroxymethylphenylsulphonylurea ( I X ) has also been identified chromatographically in From the urine of dogs given tolbutamide, Mohnike and Wittenhagen51 isolated a toxic metabolite, p-toluenesulphonamide (A') and also another compound which was later52
shown to be p-toluenesulphonylurea ( X I ) . Tolbutamide can therefore be metabolized in at least three ways: SO2.N H . CO However, there may be other species differences in the pathways of metabolism of the sulphonylurea compounds53.
Tolbutamide is rapidly eliminated by the human kidneys, mainly as the carboxylic acid. This metabolite is freely water-soluble within the physiological urinary pH range54 and the danger of crystalluria is negligible, but a white precipitate may develop on testing the urine with sulphosalicylic acid if large amounts of compound (VIZZ) are being excreted. Renal tubular transport is probably important in the excretion of the drug, as there is a much greater proportion of compound (VIZZ) in the urine compared with blood, and probenecid, which affects many other tubular transport mechanisms, delays the disappearance of tolbutamide from the serum45.
The effective and optimal dose of tolbutamide for suitable diabetic patients is 1-3 g/day, but as it is rapidly excreted, the drug must be given in divided doses every 6-8 hours. The optimal blood level is variable and ranges from 8-18 mg/100ml. Further increases in the dose are, paradoxically, associated with a diminishing hypoglycaemic effect33.
In contrast to carbutamide, thyroid function as assessed by 1311 studies3' is not significantly affected by tolbutamide. This agrees with the findings of MacKensie and M a c K e n~i e~~ that removal of the p-amino group from sulphamethyldiazine abolishes its goitre-producing properties. Tolbutamide has no antibacterial action.
Chlorpropamide
Chlorpropamide (N-propyl-N'-p-chlorobenzenesulphonylurea, Diabinese The metabolic fate of chlorpropamide after oral absorption has been studied using the radioactive 35S-labelled Absorption from the intestine is more rapid than with carbutamide or t o l b~t a m i d e~~, as maximum radioactivity and optical density is reached in 2 hours. The decay of the radioactivity (confirmed by measurement of chloroform-soluble optical density) in the blood-plasma showed that, unlike carbutamide or tolbutamide, chlorpropamide disappeared at two separate rates, a rapid one with an uncorrected biological half-life of 32 hours and a slower component with a half-time of approximately 16 days. In diabetic patients, a comparable initial rapid decline was seen, but the second component was much slower. The diabetic patients received chlorpropamide or tolbutamide therapeutically for some time before the study was made, so that this observation does not provide good evidence for the suggestion that diabetic and normal subjects handle chlorpropamide differently. On a weight for weight basis and using both duration of action and the degree of hypoglycaemia as criterion for evaluation, Roots8 showed that in rats and dogs chlorpropamide is more effective than tolbutamide. Similar comparisons were made in rhesus monkeyss9; at dose levels comparable to those used in man (5-10 mg/kg), a definite and prolonged hypoglycaemic action was obtained, whereas a dose of tolbutamide (10 mg/kg) had only minimal effect and 5 mg/kg produced a rise of blood-sugar level. These animal studies, showing that chlorpropamide has a greater and more prolonged hypoglycaemic effect than tolbutamide, have been fully confirmed in man56~60~61. The optimal therapeutic dose is between 100 and 500 mg daily, the effective blood chlorpropamide level ranging from 3-17.5 mg/lOO mLa2lW. With doses of 500 mg or more, blood levels of up to 40 mg/ml. are frequently seen. There is a fairly good relationship between the dose and blood level attained both in normal human beingsa4 and in diabetic patientsa3 but the relationship between serum level and hypoglycaemic effect varies considerably from patient to patient.
The increased hypoglycaemic potency of chlorpropamide as compared with tolbutamide is probably due to the higher initial and more prolonged blood levels attained, and not to any inherent increased cp~ten~y'42~a5, although a greater hypoglycaemic effect has been obtained with equivalent blood levels56. Studies of serum levels and blood-sugar concentration in human beings do not suggest a cumulative action in doses of 500 mg or less, either in normala4 or diabetic subjects63.
As with tolbutamide, thyroid function as assessed by plasma protein-bound iodine levels or the thyroid uptake of radioiodine, is not impaired by chlorpropamide66 and the drug has no antibacterial action.
Metahexamide
Metahexamide (N-cyclohexyl-N'-(3-amino-4-toluenesulphonyl) urea, Euglycin, V ) is a very effective hypoglycaemic agent with a duration of action comparable to that of carbutamide and a potency which is rather higher than that of chlorpropamide. I n rats it is more active than either tolbutamide or chlorpropamide on a weight for weight basisa7. In normal humans the hypoglycaemic potency of metahexamide is four times higher than chlorpropamide or tolbutamide when judged by the serum concentration attained or twice as active as chlorpropamide and fifteen times more potent than tolbutamide when assessed by weightas. Absorption from the intestine is rapid, being complete in 2-3 hours48. The biological half-time is 19-26 hours in normal p e 0 p l e~6~~~ but it may be longer in diabetic patients. 70 It is about half as effective as chloropropamide and about five times as effective as tolbutamide in producing sustained blood levelsa6. Dogs and rabbits excrete 30-35 per cent of the administered metahexamide dose unchanged in the urine and 45-50 per cent as 3-amino-4-benzenesulphonamide57. The aromatic amino group is resistant to acetylation even in rabbits, a species that acetylates carbutamide readily53. In appropiate diabetic patients, a single daily dose of 50-300 mg gives an adequate hypoglycaemic response and it compares favourably with tolbutamide and c h l~r p r o p a m i d e~~-~~. Patients resistant to tolbutamide may respond to metahexamide but those resistant to chlorpropamide usually cannot be controlled with the drugas. Gastro-intestinal and allergic side-effects are probably as frequent as with other arylsulphonyl compounds, particularily when high doses are used. No information about the effect of metahexamide on the bone marrow is available at present, but jaundice of the obstructive variety O C C U~S '~* '~~, and for this reason it is no longer used clinically.
SB 1
This compound ( N -(3-aminobenzenesulphonyl) -N'-n-butylurea,Sucrida Berna, V I ) differs from carbutamide by having the aromatic amino group in the meta instead of the para position on the benzene ring. I t has no antibacterial activity75. I n divided doses of 0-5-1.5 g daily, SB 1 produces an adequate hypoglycaemic response in selected diabetic patients76. In rabbits it is rather less toxic and somewhat more potent than tolbutamide on a weight for weight basis77. Hypoglycaemia is maximal 6-9 hours after 250 mg/kg orally and lasts for 13-15 hours. Urinary excretion of an acetylated metabolite is rapid, 40-50 per cent being eliminated in 12 hours.
Furjiuralurea
Furfuralurea (N-2'-furfuryl-N'-p-toluenesulphonylurea, VII) is mentioned by Danowski and Mateer78. Its hypoglycaemic activity is comparable to that of chlorpropamide.
The Toxicity of Tolbutanzide and Chlorpropamide in Animals and in M a n
Toxicity studies in animals with chlorpropamide and tolbutamide indicate that with both compounds the acute and chronic toxicity is 1 0~~~9~~. For tolbutamide, the oral LD5, (calculated according to the method of Litchfield and W i l c o~o n~~) in rats is 2.49 and in mice is 1.83 This lack of hepatotoxic effect contrasts sharply with the effect of tolbutamide in depancreatized and partially depancreatized dogs and puppiess0. In doses of 100-150 mg/kg, all the animals died in 3-6 weeks with severe liver damage; one out of three animals receiving 30 mg/kg (the amount usually recommended for humans) succumbed in a similar fashion. At all dose levels, the albumen and the protein-bound polysaccharide levels in the plasma declined, the serum alkaline phosphatase, glutamic-oxaloacetic and glutamic-pyruvic transaminase levels rose sharply, and in two animals the prothrombin time was prolonged terminally. This was unaffected by Vitamin K. The bromsulphalein excretion (often used as a more refined test of hepatic function in man) remained normal. These effects, which are seen in dogs, may be due to the formation of a toxic metabolite, possibly p-tol~enesulphonarnide6~. Similar hepatotoxic effects in dogs have been describeds1rs2.
When used therapeutically in man, tolbutamide, however, does not damage the liver. Repeated liver function studies have shown that changes of the serum bilirubin, flocculation tests and bromsulphalein excretion have not been seen over a period of 12-16 monthss31s4. A slight rise of serum alkaline phosphatase level has been reporteds5 but its significance is not clear. Dolgersa has given tolbutamide to several patients who recently recovered from hepatitis or obstructive jaundice, without evidence of further liver damage.
Chlorpropamide, however, may cause an intrahepatic obstructive jaundice of the type seen sometimes following chlorpromazine or methyltestosterone. This develops most commonly in patients given over 500 mg daily but it has been reported after smaller
The condition subsides rapidly on stopping the drug and evidence of permanent liver-cell damage has not, as yet, been reported. Liver biopsy material which showed histological evidence of a healing pericholangiolitis was found in one out of seven patients on chlorpropamide, and four out of six patients taking metahexamidee9. The hepatic histology was normal in all of six patients given tolbutamide.
With tolbutamide or chlorpropamide, most workers have been unable to detect any significant change in the quantity or appearance of the white blood-cells, but leucopenia has occasionally been reported. In contrast to the serious effects of carbutamide, the leucopenia is usually transient and no case of agranulocytosis has so far been recorded.
As far as important side-effects are concerned, tolbutamide and chlorpropamide are remarkably non-toxic when used in effective hypoglycaemic doses for appropriate diabetic patients. At the Joslin Clinic, since November 1957, only 1.1 per cent of 772 patients treated with tolbutamide have developed side-effects sufficiently severe to warrant stopping the drugses. Dolgere6 has seen no serious toxic reactions among 500 private patients treated for 3-1 2 months. Chlorpropamide seems equally innocuous considering the large number of patients who do not suffer from any side-effects, but a curious ataxia with muscle weakness (not due to hypoglycaemia) has been described following large dosesg0. Minor side-effects are however more frequently encountered. Both drugs may cause gastro-intestinal symptoms such as epigastric pain, nausea and diarrhoea; and, in patients with peptic ulcer, their dyspepsia may be aggravated. These features appear to be rather more common with tolbutamide than with chlorpropamide. Urticaria1 skin rashes are not uncommon and a single case of purpuria has been reported by Sugarg1. One patient nearly died of anaphylactic shock following chlorpropamideg2. During treatment with tolbutamide, flushing of the face may occur if ethanol is taken, and an antabuse-like effect may occur with chlorpropamide". Most clinical reports describe abdominal symptoms and skin rashes in 1-7 per cent of patients.
THE RELATIONSHIP BETWEEN CHEMICAL STRUCTURE AND ACTIVITY OF THE HYPOGLYCAEMIC SULPHONAMIDES

Sulphanilamidothiadiazoles
Between 1942 and 1946, L o~b a t i k r e s~~?~~ and Bovet and Dubostg5 tested many thiadiazole derivatives in dogs and rabbits during studies of the relationship between structure and hypoglycaemic activity in this series. When the alkyl group of the original compound, 5-isopropyl-2-sulphanilamido-lY3,4-thiadiazole, (I) was replaced by either methyl or ethyl radicals, the hypoglycaemic effect was reduced or even lost. Maximum activity was obtained when the alkyl chain in the 5-position was either an is0 or a tertiarybutyl group but longer hydrocarbon chains, e.g. hexyl or heptyl, produced compounds with little hypoglycaemic activity ( i -14
corresponding to the hydrocarbon chains, particularly isopropyl, butyl and pentyl alcohols, themselves have some hypoglycaemic activity, and he postulated that it was the hydrocarbon moiety that conferred hypoglycaemic activity, although the sulphanilamido portion was nevertheless essential as a 'reinforcing agent' to the rest of the molecule.
Arylsulphonylureas
Only a few of the many hundreds of sulphonylurea compounds which have now been synthesized possess sufficient hypogIycaemic potency and duration of action to justify more detailed investigation. Nevertheless, it is interesting to examine how variations in chemical structure modify hypoglycaemic activity. There is a close structural similarity between the early sulphanilamidothiadiazoles e.g. (I) and the later sulphonylureas e.g. (11). In view of this chemical resemblance, it is surprising that the hypoglycaemic effects of the sulphonylurea compounds were discovered so much later, and even then by chancez4. The discovery of the hypoglycaemic properties of carbutamide was soon followed by the discovery that the aromatic p-amino group was not necessary for hypoglycaemic a c t i~i t y 9 7 *~~ and the potent p-methyl analogue, tolbutamide, was synthesized. This compound and all subsequent ones without a free aromatic p-amino group e.g. SB 1 (VI) have no antibacterial activity. Tolbutamide, however, is a short-lived drug within the body because of the metabolic oxidation of the methyl group, and a more potent, longer-acting drug was sought, with a similarly low degree of toxicity.
The effect of change in structure of a series of sulphonylureas, ArSOz-NH. COaNHR, on hypoglycaemic activity was systematically studied by giving fasting rats a single oral dose of 10Ck.300 mg/kg of the compounde9. Modification of the urea portion led to loss of hypoglycaemic activity although weak action was retained when the NH-CO.NHBu group was replaced by a NH.CS.NHBu, NH-CO-OBu or N H C O -P h group (Table 5. branched alkyl chain (such as tertiary butyl) or a cyclic substituent have good activity; in the latter case, a five to seven carbon atom radical seems to give maximal effect e.g. metahexamide ( V ) and N-cyclohexyl-N'-ptoluenesulphonylurea which is reported to be about as active orally and intraperitoneally as tolbutamide but to have a lower toxicityloo. Compounds in which the alkyl-carrying nitrogen atom is di-substituted are moderately active. The greatest enhancement of hypoglycaemic effect is achieved, however, by substitution in the aromatic ring, Ar (Table 5 .4). Para-substitution gives the most potent and longest-acting compounds, the halogens, especially chlorine, being particularly active. The p-methoxy analogue of tolbutamide has been reported to be about as active orally as tolbutamide in rabbits and to be less toxiclo1. But substitution of groups other than methyl, methoxy or halogen in the p-position gives compounds of low activity, for example, p-isopropyl, p-carboxy, p-ethoxycarbonyl or p-hydrazinocarbony128. Unsubstituted phenyl derivatives are rather less active, and ortho-substituted and di-substituted (2,4-, 2,5-, 3,4-) phenyl compounds are even weaker28. I t is generally agreed that in mammals the sulphonylurea compounds only produce hypoglycaemia when some functioning pancreatic beta-cells are present. Houssay and Penhos1o2, for example, showed that the presence of some pancreatic tissue is essential for the hypoglycaemic effect of these compounds in much the same way that Loubati6resz2 showed that this effect was true of the sulphanilamidothiadiazoles. The sulphonylureas reduce the fasting blood-sugar level of intact and partially pancreatectomized animals or animals made mildly diabetic with alloxan, but they do not do so after total pancreatectomy in dogs, rabbits, rats, cats, toads or man46,102-7, nor in animals made severely diabetic with alloxan.
2). As with the
I n human beings, the arylsulphonylurea compounds are effective only in individuals who have a pancreatic reserve of insulin. They reduce the fasting blood-sugar concentration in non-diabetics and mild diabetics whose illness started in adult life, but with few exceptions the drugs do not act in patients with severe diabetes of the juvenile type. This may be because the pancreas of diabetic adults contains over 30 per cent of the normal insulin content, while in juvenile diabetic patients little or no insulin may be extracted from the glandlo*. In a similarway, insulin-likeactivitymay be readily detected in the plasma of many diabetic adults but generally is not found in plasma of patients with the juvenile form of the diseaselOg.
After evisceration in dogs102J06, rabbits46 and ratsllO, the drugs cease to produce hypoglycaemia. This suggests that the lowering of blood-sugar concentration is not produced by a direct action on peripheral tissues, although some studies suggest that the sulphonylurea compounds stimulate isolated excised muscle to take up glucose (see below).
However, the dependence of the hypoglycaemic action of the sulphonylurea compounds on the presence of some islet-containing pancreatic tissue only applies to mammals. Mirsky and Gitelsonlll, for example, showed that a hypoglycaemic response to tolbutamide may be obtained in alloxanized chickens and in depancreatized or enterectomized ducks. Hazelwood112 has further shown that hepatectomy, with or without pancreatectomy does not prevent the hypoglycaemic response in domestic fowls. As the carbohydrate metabolism in avians is therefore complex, all further remarks in this review will be concerned with the mode of action of the sulphonylurea compounds in mammals.
The sulphonylurea drugs may produce hypoglycaemia in mammals by inhibition of the secretion of the pituitary or adrenal glands, but this is unlikely as removal of either or both of these glands does not prevent the hypoglycaemic effects. For example, hypophysectomy in dogslo2 increases the degree of hypoglycaemia (thus simulating the effects of insulin) yet hypophysectomized cats are not more sensitive to the sulphonylurea drugs than are normal animals113. Unlike insulin, however, adrenalectomy greatly enhances their hypoglycaemic effect in both cats and dogs. The drugs are effective in patients with pan-hypopituitarism and Addison's disease, both before and after replacement therapy with hydrocorti~onell~, and the hyperglycaemic response to adrenaline is unaffected during the administration of these drugs.
The idea that the sulphonylurea compounds inhibit the release of glucagon from the alpha-cells of the pancreas was suggested in 1956 by Ferner and Runge115 who found histological evidence of damage to the alpha-cells following carbutamide. Similar changes had previously been reported after IPTD (I) 116 . The sulphonylureas however are ineffective in severe alloxan diabetes. The disappearance of l3lI-1abelled glucagon is unaffected by pretreatment with tolbutamide or carbutamidell', and the hypoglycaemic response to injected glucagon is not inhibited in man114. The possibility of tissue antagonsim to glucagon is therefore unlikely. It appears that hypoglycaemia as such may alter the staining properties and decrease the granularity of the pancreatic alpha-cells118.
From these results, the following conclusions may be drawn concerning the mechanism by which sulphonylurea compounds lower the blood-sugar level in mammals: (a) they do not possess a direct insulin-like action on peripheral tissues; (6) the presence of an insulin-containing pancreas is essential; (c) they do not act by reduction of glucagon secretion or by tissue antagonism to glucagon, and (d) inhibition of hormonal antagonists of insulin from the pituitary or adrenal glands is not involved.
Three ways of explaining the hypoglycaemic effect of the compounds therefore remain: (a) the pancreas is stimulated to release more insulin, (6) the rate of endogenous insulin destruction is diminished, and (c) hepatic glucose release and/or production is depressed.
Increased Release of Insulin from the Pancreas
This was first suggested by Loubati&resZ2 to explain the hypoglycaemic effects of IPTD and other thiadiazolylsulphonamides. In cross circulation experiments, he showed that when IPTD was injected into a dog'whose pancreatico-duodenal vein was anastomosed to the jugular vein of a depancreatized dog, the blood-sugar level of the diabetic animal was depressed. In similar experiments with intact animals previously given intravenous carbutamide, the blood-sugar level of the recipient animal is lowered by injections of the pancreatic venous blood of the donor, but not by injections of blood from the donor's mesenteric veinllO. Direct perfusion of the pancreas with tolbutamide via the right gastro-epiploic branch of the gastro-duodenal artery produced a greater reduction in the blood-sugar level than did injection into the femoral veinlZ0. But hypoglycaemia was not produced by pancreatic injection in doses which were too small to be effective when given peripherally. Other workers found that the hypoglycaemic effect when metahexamidefzl or chlorpropamide12z was injected into the pancreatic artery was no greater than when either drug was given into the femoral vein.
The response to tolbutamide is roughly proportional to the insulin content of the pancreas of the mammal. Mirsky, Perisutti and GitelsonlZ3 showed that pretreatment of dogs with growth hormone from the pituitary gland, a hormone known to deplete the pancreas of insulinfz4, reduces the acute hypoglycaemic effect of tolbutamide. Similarly, prolonged fasting, which also reduces the insulin content of the pancreaslZ5, diminishes the hypoglycaemic response. The onset of alloxan diabetes in cats is heralded by a phase of hypoglycaemia which is probably due to the release of preformed insulin from necrotic beta-cells in the pancreatic islets. Pretreatment with tolbutamide prevents this effectfz6 so the drug may reduce the amount of insulin within the islets. Four weeks after hypophysectomy in rats, the amount of insulin in the pancreas falls to about half the pre-operative level and sensitivity to tolbutamide diminishes c o r r e s p~n d i n g l y~~~. In human beings, the rate at which the blood-sugar concentration is lowered following a single dose of tolbutamide (1 g intravenously) may be used as a diagnostic test for mild diabetesl28; the decrease is more rapid and more profound in non-diabetic patients than in patients with mild diabetes. Wrenshall and HamiltonlZ9 have shown, using post-mortem material, that the levels of extractable pancreatic insulin are lower in diabetic men than women. Analysis of clinical dataf30 also indicates that adult males with mild diabetes are considerably less likely to respond to the sulphonylurea drugs than are women, a result which adds more evidence to the hypothesis that the hypoglycaemic effect of the sulphonylurea compounds is related to the reserve of pancreatic insulin.
Morphological studies of the pancreatic islet tissue in animals show that tolbutamide or carbutamide produce degranulation of the beta-cells with swelling of their nuclei; the islets increase in size and number and mitoses are more f r e q~e n t~~~J~~-~. No significant morphological changes in the islet tissue have been reported as yet in diabetic patients who have died while receiving tolb~tamidell5~~34. Histological changes in the beta-cells, however, have been correlated with changes of blood-sugar level and pancreatic insulin contentf35. I n experiments with calves, oral tolbutamide was shown to produce a transient degranulation of the beta-cells, with increase in nuclear volume and a transient reduction of extractable insulin from the pancreas. The fall in blood-sugar concentration closely paralleled these changes. Carbutamide lowers the amount of insulin extractable from the pancreas of dogs but this does not persist136. The suggestion that betacell degranulation is a specific response to the hypoglycaemic sulphonylurea compounds has been made by Creutzfeldt, Detering and Welte137, who found that large doses of two other inactive sulphonylureas (N-p-toluenesulphonyl-N'-methylurea and N-sulphanilyl-N'-ethylurea) failed to alter the histology of the beta-cells.
Perhaps, the most compelling evidencef38 that sulphonylureas produce hypoglycaemia by the release of endogenous insulin is that the insulin-like activity of pancreatic venous blood of dogs increases 'many times' after the administration of hypoglycaemic sulphonylurea~~~~. Goetz and Egdahl140 have confirmed this by assaying the ability of pancreatic venous blood of dogs given tolbutamide to lower the blood-sugar level in fasting, intact mice. In rats, a group of German workers measured the incorporation of glycogen into rat diaphragm muscle as a test for insulin and reported that the insulinlike activity of peripheral venous blood is increased by carbutamide141 and t o l b~t a m i d e~~~. Evidence concerning the effect of sulphonylureas on the plasma insulin-like substances in human beings, however, is conflicting. Venous blood taken during maximal hypoglycaemia following intravenous or oral tolbutamide fails to stimulate the uptake of glucose by the rat diaphragm muscle143. 144 . But, using a more sensitive rat diaphragm technique145, a two-fold rise of plasma insulin-like activity has recently been detected 2.5 hours after a single oral dose in normal subjects and tolbutamide-sensitive patients146. There was a correlation between the increase of glucose uptake by the rat diaphragm and the fall of blood-sugar concentration in the patients.
If the sulphonylurea compounds produce hypoglycaemia by stimulating insulin release from the pancreas, then it should be possible to demonstrate in man some of the metabolic effects of increased peripheral glucose utilization. After intra-arterial injections of insulin, the peripheral arteriovenous glucose differences of the injected limb plasma potassium and phosphate concentrations decrease, lactate and pyruvate levels rise and the respiratory quotient increases. These changes have not generally been observed following tolbutamide, carbutamide or c h l o r p r~p a m i d e~~,~~~J~ 149p160.
Such negative findings lose much of their importance, however, when it is realized that these indices of peripheral glucose utilization are relatively insensitive and liable to considerable experimental error.
Measurement of peripheral arterio-venous glucose differences are difficult to interpret, and this is particularly so when the blood-flow through the tissues, known to be increased by insulin15', is not measured simultaneously. The decrease in the blood-sugar concentration following intravenous insulin injections (or following the rise after a glucose load) is associated with a narrowing of peripheral arterio-venous glucose concentration difference~l~~ but the proportion of arterial glucose concentration taken up by the tissues (q) nevertheless where A and V are the glucose levels in artery and vein respectively. This parameter was measured folIowing large doses of intravenous tolbutamide during 5 or 10 per cent glucose infusionslo4. In mildly diabetic and in normal subjects no change was detected in the ratio -when the results were analysed statistically.
However, simultaneous blood-flow measurements were not performed, and closer scrutiny of the data shows that when definite hypoglycaemia was A -V A -V produced the ratio -increased considerably. A rise in the ratio -A A in fasting normal subjects following intravenous doses of tolbutamide has been describedlo5. Butterfield 
, Fry and H01lingl~~ developed a method for
A -V A
the simultaneous measurement of forearm blood-flow and found that there is a critical blood-sugar concentration below which glucose fails to enter cells. This threshold value is raised in diabetes and may be lowered by oral tolbutamide. When the changes in glucose uptake are slight, there is no correlation between the change of glucose assimilation and the maximal decrease in serum inorganic phosphorus c~n c e n t r a t i o n l~~. Likewise, alterations of serum pyruvate and lactate concentrations following the sulphonylureas are also in~ignificant14~, 150.156,157. Moreover, difficulties in finding consistent and unequivocal evidence of increased peripheral glucose utilization also apply to the changes following insulin. When insulin is given intravenously in doses which mimic the fall of blood-sugar level produced by tolbutamide, evidence of increased glucose uptake by the tissues is also often inconclusive, expecially if the injection is made slowly. Madison and Unger15* claim that when insulin is injected into the portal vein (thus simulating endogenous insulin secretion) little effect on peripheral arterio-venous glucose differences may be demonstrated, although equivalent doses of insulin injected into a peripheral vein are followed by an increase which is easily measured. No qualitative differences have however been observed in the serum potassium, pyruvate and lactate levels after injections of insulin into the portal vein and into the femoral veins of dogs, although different rates of insulin administration (rapidly, or 1.0 and 0.1 units/5 minutes) were employed at two different dose levels (0.1 or 1.0 units/kg150. I n intact animals, the sulphonylurea compounds increase the liver glycogen contentls9 but do not affect significantly that of muscle glycogen, whereas single injections of insulin have the reverse effect. When an intravenous infusion of insulin is given to fasting intact ratPo, the blood-sugar decreases although the muscle glycogen remains unchanged. This again emphasizes that the metabolic response is greatly affected by the route and the rate of insulin administration.
Nevertheless, there are two effects other than the hypoglycaemic action in which the sulphonylureas may mimic the metabolic effects of insulin. Firstly, tolbutamide reduces the blood amino acid level in normal subjects and in stable diabetic p a t i e n t P , and, in vitro, an increased incorporation of 14C-glycine into rat liver-slice protein has been observed157. Secondly, serum unesterified fatty acid levels are reduced by about 30 per cent following tolbutamide162 and metahexamidels3. These two findings are important as they show that the sulphonylureas do not merely produce hypoglycaemia but may also simulate some of the other effects of insulin.
Diminished Destruction of Insulin
This mechanism has been suggested since insulinase in rat liver-slices is inhibited by the sulphonylurea It is of doubtful significance, however, since insulinase is not inhibited by the concentrations of tolbutamide reached in man following therapeutic dosesls4. The rate of degration of 1311-labelled insulin in rabbits is not altered by t~l b u t a m i d e l '~.~~~ and the liver of rats pretreated with the drug destroys l3lI-labe1led insulin at the normal ratelB5. Likewise most workers have not been able to show that the sulphonylureas potentiate the effect of exogenous insulin either in severe diabetic patients or following pancreatectomy in man. However, there is considerable evidence in depancreatized dogs that large doses of carbutamide or potentiate insulin. This effect, which is obtained only after prolonged administration, is probably related to the severe hepatic damage that these compounds produce in dogs. Diminished destruction of insulin therefore is not an important effect of the sulphonylureas, but, as Mirsky suggestslZ3, inactivation of insulinase may contribute to the slow rise in the blood-sugar level following tolbutamide-induced hypoglycaemia.
Reduction of Hepatic Glucose Output by a Direct Action on the Liver
There is little doubt that tolbutamide reduces the output of glucose from the liver in human beings and in dogs. This occurs both during fasting and after fructose administration1689169 and may be measured directly by catheterization studies or indirectly by determining the specific activity of plasma glucose following injections of 14C-labelled glucose104~148J49~170~171.
Tolbutamide interferes with the in vitro conversion of liver glycogen to glucose. Large amounts added to the incubating medium prevent glucose release from both rat and rabbit l i~e r -s l i c e s~~~-~. The increased glucose output induced by adrenalin is particularly affected164. Weber and C a n t e r~l '~ found that tolbutamide inhibits glucose-6-phosphatase predominantly, slightly reduces phosphohexosisomerase activity but does not alter liver phosphoglucomutase, glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase. This suggests that tolbutamide in vitro has a specific effect on glucose-6-phosphatase but the concentrations necessary for this effect are 5-10 times higher than the peripheral blood levels which produce hypoglycaemia in vivo. Liver tissue removed from rats during tolbutamide hypoglycaemia, however, fails to show reduced glucose-6-phosphatase activity176, and many other sulphonamides or sulphonamide derivatives which do not lower the blood-sugar level may also inhibit liver glucogenic enzymes. This has recently been confirmed by Jasmin and Johnson177 who found that there is no relationship between the hypoglycaemic activity of 17 new 5-alkyl-2-benzenesulphonamido-1,3,4-thiadiazoles and their ability to inhibit glucose-6-phosphatase (using the method of Cori and C01-i~'~) in mice liver homogenates. Tolbutamide produced a 50 per cent inhibition at 5 x 1 0 -3~ concentration, and a comparable degree of inhibition was obtained with concentrations of sulphaethylthiadiazole which have antibacterial, but no hypoglycaemic, activity. The presence of the liver is not essential for the hypoglycaemic action of the sulphonylurea compounds, since hepatectomy does not prevent the hypoglycaemic response to tolbutamide. Further, moderate doses of tolbutamide produce a similar decrease in the blood-sugar concentration in hepatectomized and intact
These findings make it difficult to believe that, in therapeutic doses, the sulphonylurea compounds reduce hepatic glucose output by a direct action on the liver, and, as described above, the evidence points to the sulphonylurea compounds producing hypoglycaemia by reducing glucose release and/or dogsl6OJ 7 9. production from the liver. This apparent paradox can only be resolved if it is assumed that endogenous insulin, secreted into the portal vein, produces a diminution of hepatic glucose output. If this is not so, it is difficult to explain why the sulphonylureas are only effective in the presence of an insulin-containing pancreas, although it may be that the metabolic upset of alloxan diabetes, human juvenile diabetes and the diabetes following total pancreatectomy, masks in some way a primary hepatic effect of the drug. Our knowledge of the hepatic action of insulin is still inconclusive. An increase of hepatic glycogen under the influence of insulin can be demonstrated readily in intact animals provided the insulin is rigorously glucagonfree and no fall of blood-sugar is allowed to occur18o.
In man, the glucose output from the splanchnic area was shown by catheterization techniques to be reduced by insulinls1. Laterls2, it was suggested that insulin increased the glucose uptake by hepatic as well as by peripheral cells, but these experiments did not distinguish between the relative contributions of the liver and the rest of the splanchnic tissues, and the problem remains unsolved. Comparing the intraportal and peripheral venous routes of insulin administration in anaesth.etized dogs, Madison and Unger158 claim to have found that intraportal insulin produces a greater decrease of hepatic glucose production and a relatively smaller increase of peripheral glucose utilization than when insulin is injected into a foreleg vein. Their conclusions were based on glucose gradients without simultaneous blood-flow measurements. More recently, Shoemaker, Mahler and Ashmorels1 using direct simultaneous measurements of glucose concentration gradients across the liver, the total splanchnic bed, and the nonhepatic splanchnic tissue bed, were unable to detect any decrease of hepatic glucose output following various doses of insulin. These studies were performed in unanaesthetized dogs and were combined with simultaneous measurements of hepatic blood-flow. Tarding and Schambyel'l have also failed to show a reduction of hepatic glucose output following constant intraportal infusions of small amounts of insulin.
The rate of decay of the specific activity of plasma glucose after a single injection of 14C-labelled glucose has been used as an index of hepatic glucose After the intravenous administration of 10 units of insulin into unanaesthetized, intact dogs, a 'plateau' lasting 10-20 minutes was observed in the specific activity values. Similar effects have been reported in human beingsls4. These observations are claimed to indicate suppression of the entry of glucose into the circulation, but similar experiments using constant infusions of 14C-labelled glucose to eliminate problems of equilibrationls5 failed to confirm this interpretation. However, during a prolonged infusion of insulin, the increased hepatic glucose output in response to hypoglycaemia was held in abeyance until the infusion was stopped, and then it rose sharply.
Although the evidence from animal experiments that the sulphonylureas produce hypoglycaemia by releasing insulin from the pancreas is convincing, the only unequivocal evidence of such a mechanism in man is that juvenile diabetic and pancreatectomized patients do not respond to the drugs. Reduction of glucose production in the liver appears to be the reason for the decrease in the blood-sugar level after the administration of sulphonylurea compounds. This may be produced pharmacologically by a direct, possibly enzymic, effect on the liver or physiologically by an increased output of endogenous insulin. The answer to this problem will probably not be found until our knowledge of the hepatic effect of insulin is more precise. Both mechanisms may operate, and a direct action on the liver-cells may allow endogenous insulin to reduce the hepatic glucose output.
Extrapancreatic Effects of Sulphonylurea Compounds
The in vitro effects of sulphonylureas on isolated tissues other than the liver are still largely unexplored. This type of study is important not so much to further our understanding of the mechanism of the fall in blood-sugar produced by the drugs, but to explore the possible ways in which insulin release from the pancreas is accomplished and to detect any secondary effects which may be harmful.
Most workers have been unable to detect any increase in the rate of glucose uptake by the rat hemidiaphragm or in the incorporation of glycogen into diaphragm muscle, when incubations are carried out in bicarbonate buffer with high concentrations of t o l b~t a m i d e l~~~~~~ or carbutamidelas. I t has been further shown that the stimulating effect of insulin on glucose uptake by the diaphragm is unaffected by tolbutamide1a7.
However, Raphaelsonlag found that both carbutamide and tolbutamide considerably increase the glucose uptake by the diaphragm at a comparable sulphonylurea concentration. He found considerable variation at a given drug concentration and there was no suggestion of a dose-response relationship. Similar findings have also been reported elsewherelgOJgl. These different results are difficult to explain at the present time and further work is required.
Tolbutamide and chlorpropamide stimulate the rate of oxidation of 14C-labelled glucose to carbon dioxide by the rat epididymal pad of fat and diminish the incorporation of glucose into lipidlg2. Further experiments with g l u c o~e -l -~~C and g l~c o s e -6 -~~C show that most of the increased carbon dioxide production arises from carbon-1 of the glucose molecule, suggesting stimulation of the phosphogluconate oxidative pathway. Increased glucose oxidation is generally accompanied by increased synthesis of fatty acid from glucose carbonlg3 so the significance of this finding is uncertain.
Slices of liver tissue removed from rats fasted for 48 hours show considerable inhibition of ketogenesis when incubated with chlorpropamide or tolbutamide at concentrations within the expected therapeutic range, and this effect is not altered by using liver tissue from pancreatectomized or alloxanized animals192. The relationship of this finding to the production of hypoglycaemia is obscure. Bornsteinlg4 has reported that hepatic alanine transaminase is inhibited in vitro by sulphonylureas.
These scattered, preliminary observations are compatible with the hypothesis that the sulphonylureas affect enzyme reactions which depend upon pyridine nucleotides as co-factorslg5.
The sulphonylurea compounds are only effective in patients with mild diabetes of the late-onset or adult type; 60-70 per cent of the diabetic population belong to this group. They are not insulin-deficient (as defined above) and they have no tendency to develop diabetic ketosis. In contrast, the sulphonylureas are useless in patients with severe diabetes of the juvenile type, who are insulin-deficient and need daily injections of insulin to maintain good health. Sulphonylurea compounds do not usually allow a reduction of the insulin dose in these patients, and a labile or 'brittle' diabetic patient cannot be made more stable.
The majority of patients with mild diabetes of the adult type are obese, and weight reduction with adequate restriction of carbohydrate in the diet will often control their symptoms and hyperglycaemia. There is, however, a small group of middle-aged or elderly diabetic patients, constituting perhaps 5-10 per cent of the total diabetic population whose diabetes has developed late in life; they have little or no tendency to ketosis, they are often under-weight, and their hyperglycaemia . cannot be adequately controlled by diet alone. These patients would otherwise require insulin and will benefit most from treatment with the sulphonylurea compounds.
Patients suitable for treatment with the sulphonylurea compounds can usually be selected on clinical grounds alone although this may be difficult if the patient is already taking insulin. Objective tests, therefore, have been devised to assess the likelihood of a reasonable therapeutic response to tolbutamide. At the Joslin Clinica3 a single 3-g oral dose of tolbutamide is given during fasting; after 4 hours, the blood-sugar in patients expected to respond to the drug falls to 100mg/lOO ml., or less (Somogyi-Nelson technique). Patients with a fasting blood-sugar of over 250 mg/100 ml. generally do not show the requisite reduction in the blood-sugar and are usually unsuitable for treatment with tolbutamide. Selection by this method is stringent and reasonably reliable, but some suitable patients may be missed. Duncan, Lee and YounglS6 used the development of ketoacidosis as a n index of response to tolbutamide; if ketones appear in the urine 8 hours after the last insulin dose, oral therapy is contra-indicated, but if no ketones have appeared within 24 hours, treatment with tolbutamide will usually be successful. There are, however, some patients unresponsive to tolbutamide who do not easily develop ketosis. Thus, the best method of selection is a therapeutic trial. This is best carried out by using placebo t a b l e t~'~~P~ but great care must be taken with patients already receiving insulin, and the change-over is best performed in hospital if the patient is not of the maturity-onset type.
About 5-10 per cent of patients who initially respond well to tolbutamide cease to do so after some months of treatment. Dietary indiscretions may explain a few of these cases, but there are many who appear to develop a genuine resistance to the drug. When assessed in hospital, hyperglycaemia persists despite large doses and a rigid diet, and the drug may be stopped without any further rise of the blood-sugar levePSa. An 'exhaustion' of the pancreatic beta-cells may be produced due to repeated stimulation, although Pfeifferlg9 has found that the dose of insulin needed afterwards is no higher than that needed before tolbutamide was begun, and chlorpropamide is often successfuls0. Nevertheless, following a period of insulin treatment, many of these patients may again respond to tolbutamide.
Sulphonylureas should only be used when frequent and detailed observation of the patient is possible. The long-term toxicity is unknown so that sulphonylurea treatment is only justified if hyperglycaemia is adequately controlled. A high renal threshold for glucose makes urine sugar-testing a poor index of blood-sugar concentration in many of the diabetic patients who are suitable for the sulphonylureas, and, therefore, frequent blood-sugar estimations should be performed. Ketoacidosis may occur at the time of changing over from insulin or it may appear rapidly during the course of an acute infection. Even without ketonuria, serious hyperglycaemia due to acquired resistance may develop insidiously. Hypoglycaemia is rare with tolbutamide but prolonged hypoglycaemia is an important danger with chlorpropamide. Like the hypoglycaemia of the long-acting insulin preparations, it may only respond slowly to glucose administration. Obesity with its attendant dangers develops easily and excessive weight gain can only be avoided by careful supervision of the patient's diet. I t is important that the sulphonylurea compounds directly inhibit enzyme systems in the liver (and possibly elsewhere) as any drug which chronically affects hepatic function may ultimately damage the liver cells. I t is too early to say whether the incidence of 'degenerative' complications of diabetes mellitus will be affected by treatment with tolbutamide. Better control of hyperglycaemia tends to reduce the risk of complications but any drug which increases the tendency to haemorrhage must be used with great caution, particularly in patients with retinopathy. Carbutamide increases capillary fragility200 but careful studies have failed to reveal any difference in the incidence of haemostatic abnormalities between insulin-treated and tolbutamide-treated patients201.
THE GUANIDINE DERIVATIVES
Synthalin ( H I ) was discovered in Minkowski's clinic in Breslau in 1926, after earlier scattered reports that administration of guanidine (XIII) lowers the blood-sugar concentration201a. Since guanidine is a highly toxic substance, particularly to the liver, attempts were made to produce com- pounds which were less toxic but still exerted a hypoglycaemic action3. As the substituent side-chains were made longer, the compounds became less toxic and more effective as hypoglycaemic agents. For example, agmatine ( X I V ) is less toxic and more hypoglycaemic than guanidine and the pentamethylene and hexamethylene homologues are even better. The two synthalins, ( X U )
are equally efficacious and show high hypoglycaemic activity.
de Bod0 and Markszoz showed that synthalin inhibits tissue respiration but increases the glucose uptake into muscle with a concomitant increase of lactic acid production, thus simulating some of the effects of anaerobic glycolysis. Synthalin was used extensively in diabetic patients during the late 1920's but following reports by Bertram5 in 1927 that large doses may produce histological changes in the liver and kidney of animals within a few days, the drug fell into disfavour, although it was still used sporadically throughout the 1930's.
(C H2)* . NH . C . NH I n 1957 the hypoglycaemic effect of N1-/?-phenethylformamidinyliminourea hydrochloride or phenethylguanylguanidine (DBI, phenformin, Dibotin, X V ) was described by Ungar, Freedman and Shapiro203. As will be seen from formulae ( H I ) and ( X V ) , the drug has only a general structural resemblance to synthalin. The chemical properties of phenformin are given by Shapiro, Parrino and Freedman204. Hydrolyses suggested that it is stable in strongly acidic solutions and that it can be degraded in hot alkaline solutions to p-phenethylguanidine, p-phenethylurea and p-phenethylamine. Attempts at alkylation with alkyl halides yielded the corresponding hydrohalide salts. The same workerzo5 synthesized a large number of arylbiguanides of the type:
where R represented mono-, di-or tri-substitution with alkyl, alkoxy, amino, arylamino, halogen, hydroxy, or R and R' combined to give a heterocyclic ring, or where R' was hydrogen, methyl or ethyl. None of these compounds, however, showed oral hypoglycaemic activity approaching that of phenformin. A very large number of N'-alkyl-and aralkylbiguanides of R \ / I I II the type NGNH.C.NH, were then preparedzo0 and many of them R'
NH NH showed good oral hypoglycaemic activity. In the series R = alkyl, the activity reached a peak with n-pentyl, then diminished through n-octyl and disappeared with n-decyl. In comparison, branched or cyclic structures showed less activity. The most effective variant of R' was hydrogen. I n the aralkyl series, good activity occurred with R = benzyl and peak effects were obtained with thep-chlorobenzyl and /?-phenethyl (phenformin, X V ) compounds. Lengthening of or substitution on the alkylene chain diminished or abolished activity. In a series of N1, N5-substituted biguanides (XVI) good hypoglycaemic activity was attained, particularly when N5-methyl or N5-dimethyl substituents were introduced in physiologically active N1-substituted biguanides,"'. However hypoglycaemic N1,N5-substituted biguanides were found to be less easily absorbed from the gastro-intestinal tract than the corresponding N1-substituted compounds.
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The most active compounds had R2 = H, R3 = R4 = Me and R1 = Bu or PhCH,. Generally, the most active of these compounds also produced the most side-effects.
In 1929, Slotta and Tschesche208 synthesized a series of biguanides and examined them for hypoglycaemic activity. The most active compound was NN-dimethylguanylguanidine, ( NN-dimethylbiguanide, metformin, Glucophage, XVII) and this has recently reappeared for clinical trial. It produces a fall of blood-sugar concentration but gastro-intestinal side-effects were seen in five out of eight diabetic patients70. Other workers claim less gastrointestinal disorder when it is compared with phenformin2088.
Me,NC.NHC.NH,ZHCI
II II (XVII) Up to the time of writing, no means of estimating the biguanides in biological fluids have been developed, so that there is little or no information about their intestinal absorption or metabolic fate. Based on the doses necessary to lower the blood-sugar level, it seems that phenformin is absorbed to a greater extent than metformin. One study using 14C-labelled phenformin has shown that radioactivity becomes concentrated in the stomach and liver with less in muscle20sb.
The mode of action of these compoundszo6c is different from that of the sulphonylureas as the drugs produce hypoglycaemia in pancreatectomized animals20B, in severe alloxan diabetes203 and in patients with the juvenile or insulin-deficient type of diabetes210. In spite of the differences of detailed chemical structure, the recently synthesized diguanides affect biological tissues in much the same way as synthalin.
Phenformin increases the glucose uptake by the rat diaphragm in vitro, but the muscle glycogen content decreases211; there is also a marked increase in lactic acid production and a decrease in oxygen consumption. This suggests that phenformin stimulates anaerobic glycolysis by inhibiting oxidative enzyme systems, thereby mimicking the metabolic effect of severe muscular effort. Similar in vitro effects have been described with rat or guinea-pig liver slices212; glucose output is not reduced and there is no inhibition of glucose-6-phosphatase. Using adipose tissue, Wick, Larson and Serif213 have also shown that phenformin in vitro inhibits the oxidation of glucose, acetate and succinate by adipose tissue and also considerably reduces fat synthesis. Similar results have been obtained in vivo. Hepatic glycogen is reducedZ1l and there is a decreased, hyperglycaemic response to glucagon and adrenalinezo9. Muscle glycogen is also reduced and blood lactate levels rise. Diaphragm muscle, adipose tissue and liver slices from phenformin-treated animals do not incorporate 14C into protein or fat when incubated with 14C-gl~~osez14. In man, the blood pyruvate and lactate levels are raised215 and the alkali reserve is lowered. In diabetic patients treated with phenformin, this may lead to a dangerous acidosis with ketonuria, although there is a normal blood-sugar concentrationZl6. Hypoglycaemia cannot be obtained in normal humans2l5 although with intact animals a decrease in the bloodsugar concentration is easily produced. In man, there is no change in hepatic vein glucose, urea, pyruvate or lactate nor in the oxygen consumption of the liver2l7. Lactate levels in the blood from the femoral artery also remain unchanged. These results confirm that the effects of phenformin are largely mediated on the peripheral tissues.
The evidence therefore suggests that tissue anoxia is produced but how this is brought about is unknown. It may be attributed to inhibition of cytochrome oxidase and succinc dehydrogenaseZ1z*zls, but a decrease in oxidative phosphorylation would have the same result. Many factors which inhibit oxidative phosphorylation increase the glucose uptake in the rat diaphragm2l9. Later work suggests that biguanides do not reduce oxygen uptake by liver mitochondriazz0 but inhibit the transfer of energy-rich phosphate bonds to adenosine diphosphatezzl.
Clinically, the biguanides are important because, if tolerated, they would be useful in controlling the hyperglycaemia of all types of diabetes. However, the therapeutic dose of phenformin is too near the toxic one, and produces severe anorexia, nausea and vomiting in about 40 to 50 per cent of patients. Weakness, lethargy and weight loss may develop laterzzz. Despite the fact that toxic damage to the renal tubules has been reported in the rabbitzz3 and in the guinea-pigzz4 after large doses of phenformin, no serious toxic effects have been reported in humans during the past 2 years and repeated liver function studies have shown that phenformin, in contrast to synthalin, does not produce any hepatic abnormalityzz5~2z6. The apparent lack of hepato-toxic effects may be related to the fact that biguanides are able to form stable chelate rings. Krall, White and Bradleyzz7 have shown, however, that phenformin combined with insulin may make a labile or 'brittle' diabetic patient more stable, and this may prove to be its main clinical application unless a less toxic derivative is discovered.
EVALUATION OF HYPOGLYCAEMIC ACTIVITY
The preliminary testing of compounds for hypoglycaemic activity may be carried out on rats, from which food has been withdrawn for 18 hours. For general screening purposes, the compound is given orally at a dose level of 100-300 mg/kggg and the blood glucose concentration is determined on samples taken from the tail vein at 1,2, 3, 5, and 7 hours after administration. A measure of the degree and duration of the hypoglycaemia is then calculated, and used to plot dose-response curve^^^,^^. Rabbits, cats, dogs, guinea-pigs and monkeys have been used for extending the scope of these preliminary tests203.
Compounds such as tolbutamide and chlorpropamide also exert their hypoglycaemic effect when given intravenously, after they have been dissolved in water containing sufficient 0.1 N sodium hydroxide solution to bring the pH to 8-967. Other compounds such as phenformin produce hypoglycaemia on subcutaneous injection into guinea-pigs but fail to lower the blood glucose concentration in dogszo3.
Animals in which diabetes is artificiaIIy induced are used in further studies. This may be achieved either by means of alloxan injections which destroy the insulin-producing beta-cells of the pancreas or by total pancreatectomy. Rats become diabetic when given alloxan monohydrate intravenously (40 mg/kg) 53 or intraperitoneally (250 mg/kg) 203, but rabbits and monkeys need a higher intravenous dose (1 50-200 mg/kg) 533203.
Dogs may be made diabetic by an intravenous injection of 75 mg/kg of alloxan monohydrate or by removal of the pancreass3. After injection or pancreatectomy, the animals are kept in metabolism cages so that a regular check may be kept on urine volume, urine sugar excretion, and food consumption. It is of interest that injections of alloxan do not produce diabetes in the guinea-pig2z8.
Variation in the effect of a compound within an animal species is often high and it is essential to have a sufficient number of animals for each dose level for the results to be analysed ~t a t i s t i c a l l y~~~~~~. Compounds such as the sulphonamides do not generally produce hypoglycaemia in severe alloxan-diabetic animals or after total removal of the pancreas, whereas other compounds such as phenformin do so in these conditions. When highly potent hypoglycaemic drugs are undergoing toxicity studies, the possibility that death is the result of a hypoglycaemic convulsion must be borne in mind.
